Abstract: Objective To elucidate the curative effects and toxicity of bortezomib on refractory or relapsed light-chain multiple myeloma （MM）. Methods Fourteen patients with refractory or relapsed light-chain MM were treated with BD/BP, BAD/BAP, and BAEP or BVAD. Results The complete, near complete, and partial remission rate was 7.1%（1/14）, 14.2%（2/14）, and 35.7%（5/11）, respectively, with an overall response rate of 57.1%. The response rate of patients with and without renal impairment was similar. The main toxicities were languor, gastrointestinal side effects, peripheral neuropathy, thrombocytopenia. Conclusion Patients with refractory or relapsed MM resistant to chemotherapy can respond to bortezomib. The regimen is safe and its side effects are tolerable.